Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

2.85
-0.0400-1.38%
Post-market: 2.850.00000.00%19:30 EDT
Volume:421.92K
Turnover:1.21M
Market Cap:264.11M
PE:-19.71
High:2.94
Open:2.90
Low:2.82
Close:2.89
52wk High:10.40
52wk Low:2.26
Shares:92.67M
Float Shares:87.17M
Volume Ratio:0.53
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1446
EPS(LYR):-0.5438
ROE:-12.80%
ROA:-9.70%
PB:2.35
PE(LYR):-5.24

Loading ...

Anavex Life Sciences Corp Expected to Post a Loss of 8 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Anavex Life Sciences Aims to Refresh Board with Two New Candidates

Dow Jones
·
Aug 03

Anavex Urges Investors to Reject PVG Proxy Bid to Replace Entire Board at 2026 Annual Meeting

Reuters
·
Aug 03

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

THOMSON REUTERS
·
Aug 03

Anavex Life Sciences Corp - Nominates Gautam Patel and Adrian Senderowicz as Independent Directors

THOMSON REUTERS
·
Aug 03

Anavex Life Sciences Corp - Urges Stockholders to Reject Pvg Asset Management and Patrick S. Adams Control Attempt

THOMSON REUTERS
·
Aug 03

Anavex Life Sciences Corp - Files Preliminary Proxy Statement with SEC on July 31, 2026

THOMSON REUTERS
·
Aug 03

Anavex Life Sciences Corp - Christopher Missling and Steffen Thomas to Leave Board After 2026 Annual Meeting

THOMSON REUTERS
·
Aug 03

Promising Penny Stocks To Consider In August 2026

Simply Wall St.
·
Aug 03

Anavex Urges Vote for Its Six Director Nominees as PVG Group Seeks Board Seats Ahead of Annual Meeting

Reuters
·
Aug 01

Werewolf Therapeutics Posts Q2 Profit on Jazz Asset Sale

Reuters
·
Jul 31

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

Anavex Life Sciences Corp Reports Results for the Quarter Ended March 31 - Earnings Summary

Reuters
·
Jul 31

Anavex Life Sciences Q2 EPS $(0.06) Beats $(0.08) Estimate

Benzinga Earnings
·
Jul 30

Disc Medicine Posts Smaller-than-expected Q2 Net Loss

Reuters
·
Jul 30

Anavex Life Sciences Q2 Net Loss Narrows on Lower R&D Costs

Reuters
·
Jul 30

Anavex Life Sciences Reports Preliminary Q2 Net Loss Of $0.06 Per Share vs. $0.13 A Year Ago; $127.4M Cash Funds Operations Into Mid-To-Late Fiscal 2028

Benzinga Earnings
·
Jul 30

Anavex Life Sciences Q3 EPS USD -0.06

THOMSON REUTERS
·
Jul 30

Anavex Life Sciences Q3 Net Income USD -5.3 Million

THOMSON REUTERS
·
Jul 30

Press Release: Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Jul 30